Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Sees Large Volume Increase – Here’s Why

Shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) saw unusually-high trading volume on Wednesday . Approximately 31,853 shares traded hands during trading, a decline of 36% from the previous session’s volume of 49,568 shares.The stock last traded at $14.2550 and had previously closed at $14.80.

Analyst Ratings Changes

ARMP has been the topic of a number of research reports. HC Wainwright boosted their target price on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 23rd. JonesTrading initiated coverage on shares of Armata Pharmaceuticals in a report on Monday, January 5th. They set a “buy” rating and a $15.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $15.00.

Armata Pharmaceuticals Stock Performance

The firm has a 50-day moving average price of $10.25 and a 200-day moving average price of $7.50. The stock has a market cap of $509.27 million, a PE ratio of -2.88 and a beta of 1.38.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($3.23). The firm had revenue of $1.09 million during the quarter, compared to analysts’ expectations of $0.74 million.

Hedge Funds Weigh In On Armata Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in Armata Pharmaceuticals in the 4th quarter worth about $108,000. Millennium Management LLC purchased a new position in Armata Pharmaceuticals in the 4th quarter worth about $164,000. OMERS ADMINISTRATION Corp purchased a new position in Armata Pharmaceuticals in the 4th quarter worth about $177,000. SeaCrest Wealth Management LLC raised its position in Armata Pharmaceuticals by 17.3% in the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock worth $274,000 after buying an additional 6,034 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in Armata Pharmaceuticals in the 4th quarter worth about $284,000. Hedge funds and other institutional investors own 3.57% of the company’s stock.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.